Evidence map›Paper›PMID 38380944›Full record

ArticleThe journal of pathology. Clinical research2024

Aberrant PRDM2 methylation as an early event in serrated lesions destined to evolve into microsatellite-instable colorectal cancers.

David Efwm van Toledo, Arne Gc Bleijenberg, Andrea Venema, Mireille J de Wit, Susanne van Eeden, Gerrit A Meijer, Beatrice Carvalho, Evelien Dekker, Peter Henneman, Joep Eg IJspeert and 1 more

Open access · goldAbstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Endoscopic Assessment and Management of Colorectal Serrated Lesions: Current Comparative Practice, Challenges, and Future Directions.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026
    Review
  2. PRDM Proteins Orchestrate Colorectal Cancer Tumorigenesis.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

David Efwm van ToledoDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands.
Arne Gc BleijenbergDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands.
Andrea VenemaDepartment of Human Genetics, Epigenetics of disease, Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam University Medical Centers, Location Academic Medical Center, Amsterdam, The Netherlands.
Mireille J de WitDepartment of Pathology, Amsterdam, Amsterdam University Medical Centers, Location Academic Medical Center, The Netherlands.
Susanne van EedenDepartment of Pathology, Amsterdam, Amsterdam University Medical Centers, Location Academic Medical Center, The Netherlands.
Gerrit A MeijerDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0003-0330-3130
Beatrice CarvalhoDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Evelien DekkerDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands.ORCID 0000-0002-4363-0745
Peter HennemanDepartment of Human Genetics, Epigenetics of disease, Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam University Medical Centers, Location Academic Medical Center, Amsterdam, The Netherlands.ORCID 0000-0003-2179-7808
Joep Eg IJspeertDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands.
Carel Jm van NoeselDepartment of Pathology, Amsterdam, Amsterdam University Medical Centers, Location Academic Medical Center, The Netherlands.ORCID 0000-0001-7907-7390
Amsterdam UMC Location University of Amsterdam · NLThe Netherlands Cancer Institute · NL

Funding

KWF Kankerbestrijding 19221
6 · The paper itself

Abstract

Up to 30% of colorectal cancers (CRCs) develop from sessile serrated lesions (SSLs). Within the serrated neoplasia pathway, at least two principally distinct oncogenetic routes exist generating microsatellite-stable and microsatellite-instable CRCs, respectively. Aberrant DNA methylation (DNAm) is found early in the serrated pathway and might play a role in both oncogenetic routes. We studied a cohort of 23 SSLs with a small focus (<10 mm) of dysplasia or cancer, 10 of which were MLH1 deficient and 13 MLH1 proficient. By comparing, for each SSL, the methylation status of (1) the region of dysplasia or cancer (SSL-D), (2) the nondysplastic SSL (SSL), and (3) adjacent normal mucosa, differentially methylated probes (DMPs) and regions (DMRs) were assessed both genome-wide as well as in a tumor-suppressor gene-focused approach. By comparing DNAm of MLH1-deficient SSL-Ds with their corresponding SSLs, we identified five DMRs, including those annotating for PRDM2 and, not unexpectedly, MLH1. PRDM2 gene promotor methylation was associated with MLH1 expression status, as it was largely hypermethylated in MLH1-deficient SSL-Ds and hypomethylated in MLH1-proficient SSL-Ds. Significantly increased DNAm levels of PRDM2 and MLH1, in particular at 'critical' MLH1 probe sites, were to some extent already visible in SSLs as compared to normal mucosa (p = 0.02, p = 0.01, p < 0.0001, respectively). No DMRs, nor DMPs, were identified for SSLs destined to evolve into MLH1-proficient SSL-Ds. Our data indicate that, within both arms of the serrated CRC pathway, the majority of the epigenetic alterations are introduced early during SSL formation. Promoter hypermethylation of PRDM2 and MLH1 on the other hand specifically initiates in SSLs destined to transform into MLH1-deficient CRCs suggesting that the fate of SSLs may not necessarily result from a stochastic process but possibly is already imprinted and predisposed.

Indexed as

AdenomaColorectal NeoplasmsCell Transformation, NeoplasticDNA-Binding ProteinsDNA MethylationHistone-Lysine N-MethyltransferaseHumansMicrosatellite RepeatsNuclear ProteinsPromoter Regions, GeneticTranscription FactorsDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseNuclear ProteinsPRDM2 protein, humanTranscription Factorscolorectal cancermethylationserrated neoplasia pathwaysessile serrated lesions

Identifiers

PMID38380944
PMCPMC10880511
OpenAlexW4392004601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.